Real-world persistence with dupilumab among adults with atopic dermatitis

Atopic dermatitis (AD) is a chronic inflammatory skin disease with a prevalence of 5-10% among adults in the United States, and approximately 4% among adults in Europe.1,2 AD is associated with up-regulation of type 2 immune responses (including those involving type 2 helper T cells) and skin barrier dysfunction.3-7 Clinical characterization includes the presence of pruritus (itch) and eczematous lesions, with itching, skin pain, sleep and mental health disturbances among the most common patient complaints.

Source: Annals of Allergy, Asthma and Immunology - July 29, 2020 Category: Allergy & Immunology Authors: Jonathan I. Silverberg, Emma Guttman-Yassky, Abhijit Gadkari, Andreas Kuznik, Usha G. Mallya, Vera Mastey, Haixin Zhang, Zhen Chen, Cheng Chen, Andrew Korotzer, Debra Sierka, Miriam C. Fenton, Mandeep Kaur, Jessica.J. Jalbert Source Type: research